UroGen Pharma Ltd (URGN)

UroGen Pharma Ltd (URGN) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.7B; returns 1 day -1.9%, 1 week -0.2%, 1 year +99.0%.

UroGen Pharma Ltd. is a commercial-stage biotechnology company focused on developing and commercializing innovative therapies for urothelial and specialty cancers, primarily leveraging its proprietary RTGel reverse-thermal hydrogel technology.

Groups URGN belongs to

• Biotechnology
• Oncology
• Commercial Stage Biotech
• Healthcare
• Life Sciences
• Biopharmaceutical
• Israel
• Pharmaceuticals
• Cancer Therapeutics

URGN financial model: income statement, cash flow and balance sheet